End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.85 EUR | 0.00% | +1.19% | -58.33% |
May. 14 | Biophytis unveils design for obesity study | CF |
May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Sales 2024 * | - | Sales 2025 * | 4.8M 5.21M | Capitalization | 2.09M 2.27M |
---|---|---|---|---|---|
Net income 2024 * | -19M -20.62M | Net income 2025 * | -16M -17.36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.44 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
1st Jan change | Capi. | |
---|---|---|
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock